Fuyuhiko Tamanoi, Ph.D.

Professor Emeritus

310-2067318

1602 Molecular Sciences Bldg, 405 Hilgard Avenue

Website

Research Interests

UCLA-Kyoto University Academic Exchange: Kyoto University (KU) and UCLA share academic interests and collaborate to develop and exchange knowledge in areas of mutual expertise. During his visit to KU, Chancellor Gene Block inaugurated the Quantum Nano Medicine Research Center that was established in 2019. Both institutions have organized several online seminar series on topics such as New Developments in Cancer Research, COVID-19 Biology, Chemical Biology – HIV Therapy, and Molecular Biology Approaches.

Signal Transduction:  The Ras superfamily G-proteins function as a molecular switch to regulate signaling pathways.  Currently, we are investigating a unique subfamily called Rheb G-protein.  Initially, Rheb was found in brain, but was later found to be ubiquitously expressed.  We have identified Rheb homologues in a number of organisms including fruit fly and yeasts, and defined unique features of this family of G-protein.  Genetic studies using fission yeast as well as Drosophila showed that Rheb plays critical roles in cell growth and regulation of cell cycle at the G1/S boundary.  In addition, yeast Rheb regulates amino acid uptake.  The effect of Rheb on cell growth is mediated by its role in the activation of the TOR/S6K signaling pathway. Rheb is downregulated by Tsc1/Tsc2 complex that acts as a GTPase activating protein (GAP) for Rheb.  Mutations in the Tsc1 or Tsc2 gene leads to genetic disorder called tuberous sclerosis that is associated with the appearance of benign tumors at multiple sites in the body.  Our current effort is aimed at defining proteins involved in the Rheb signaling pathway.

Articles related to this research area

Nanodelivery of anticancer drugs:  Another research interest of our lab is utilization of silica nanoparticles for controllable drug delivery system for cancer therapy.  One of the major problems in clinical use of anti-cancer drugs is that many of them are hydrophobic, which poses a critical obstacle for cancer therapy.  We have used mesoporous silica nanoparticles prepared in the presence of surfactants.  These nanoparticles have the diameter of approximately 130 nm and contain thousands of pores whose diameter is about 3 nm.  We incorporated different hydrophobic anticancer drugs, such as camptothecin (CPT) and taxol, into the pores of the mesoporous silica nanoparticles and delivered the drug to a variety of human cancer cells.  This caused cell death.  We are also exploring ways to use molecular valves to carry out controlled release of anti-cancer drugs with the mesoporous silica nanoparticles.  One approach is to use molecules that change conformation by light exposure to accomplishcontrolled delivery.  Targeting to cancer by attaching ligands specific to cancer cells is currently being investigatedin our lab.

Articles related to this research area

Protein lipidation and prenyltransferase inhibitors:  Protein prenylation is aposttranslational modification of proteins involving the addition of isoprenoids, intermediates in cholesterol biosynthesis.  Two types of modification, farnesylation and geranylgeranylation, occur with a variety of proteins.  Farnesylation is of particular interest, since many of these farnesylated proteins are involved in signal transduction.  Farnesylated proteins include Ras superfamily G-proteins as well as tyrosine phosphatases.  Farnesylation is catalyzed by protein farnesyltransferase which recognizes the CysAAX motif at the C-termini of substrate proteins and transfers a farnesyl group forming a thioether bond. This heterodimeric enzyme is conserved from yeast to human, and their genes have been identified in a variety of organisms.  Small molecule inhibitors of protein farnesyltransferase have been studied.  These inhibitors, called FTIs, block anchorage-independent growth of a wide variety of human cancer cells.  A number of animal studies have shown that FTIs inhibit the growth of tumors or even regress tumor growth and clinical trials of FTIs are ongoing.  Our study focuses on the mechanism how FTI affects human cancer cells.  More recently, we have also identified small molecule inhibitors of protein geranylgeranyltransferase I.  These compounds are identified from a novel library of allenoate derived compounds.  Our GGTIs inhibit proliferation of human cancer cell lines causing G1 cell cycle arrest.

Articles related to this research area

 

Publications

  1. Tamanoi, F., Uchida, T., Egami, F. and Oshima, T. (1976) Synthesis of various phosphodiesters and phosphomonoesters with ribonuclease N1. J. Biochem. 80, 27-32.

 

  1. Hirose, S., Okazaki, R. and Tamanoi, F. (1973) Mechanism of DNA chain growth. XI. Structure of RNA-linked DNA fragments of E. coli. J. Mol. Biol. 77, 501-517.

 

  1. Okazaki, R., Okazaki, T., Hirose, S., Sugino, A., Ogawa, T., Kurosawa, Y., Shinozaki, K., Tamanoi, F., Seki, T., Machida, Y., Fujiyama, A. and Kohara, Y. (1975) Discontinuous replication in prokaryotic systems. In: DNA Synthesis and Its Regulation, Vol. III. (M. Goulian & P. Hanawalt, eds.; F. Fox series ed.) ICN-UCLA Symposium on Molecular and Cellular Biology, W.A. Benjamin, California, p.832.

 

  1. Tamanoi, F., Okazaki, T. and Okazaki, R. (1977) Persistance of RNA attached to nascent short DNA pieces in Bacillus subtilis cells defective in DNA polymerase I. Biochem. Biophys. Res. Commun. 77, 290-297.

 

  1. Tamanoi, F. and Okazaki, T. (1978) Uracil incorporation into nascent DNA fragments of thymine requiring mutant of B. subtilis 168. Proc. Natl. Acad. Sci. USA 75, 2195-2199.

 

  1. Okazaki, T., Kurosawa, Y., Ogawa, T., Seki, T., Shinozaki, K., Hirose, S., Fujiyama, A., Kohara, Y., Machida, Y., Tamanoi, F. and Hozumi, T. (1979). Structure and metabolism of the RNA primer in the discontinuous replication of prokaryotic DNA. Cold Spring Harbor Symp. Quant. Biol. 43, 203-219.

 

  1. Tamanoi, F., Machida, Y. and Okazaki, T. (1979) Uracil incorporation into nascent DNA by B. subtilis and E. coli. Cold Spring Harbor Symp. Quant. Biol. 43, 239-242.

 

  1. Richardson, C.C., Romano, L.J., Kolodner, R., LeClerc, J.E., Tamanoi, F., Engler, M.J., Dean, F.B. and Richardson, D.S. (1979) Replication of bacteriophage T7 DNA by purified proteins. Cold Spring Harbor Symp. Quant. Biol. 43, 427-440.

 

  1. Campbell, J.L., Tamanoi, F., Richardson, C.C. and Studier, F.W. (1979) Cloning of the T7 genome in E. coli: Use of recombination between cloned sequences and bacteriophage T7 to identify genes involved in recombination and a clone containing the origin of T7 DNA replication. Cold Spring Harbor Symp. Quant. Biol. 443, 441-448.

 

  1. Tamanoi, F., Saito, H., and Richardson, C.C. (1980) Physical mapping of primary and secondary origins of bacteriophage T7 DNA replication. Proc. Natl. Acad. Sci. USA 77, 2656-2660.

 

  1. Saito, H., Tabor, S., Tamanoi, F., and Richardson, C.C. (1980) Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. Proc. Natl. Acad. Sci. USA 77, 3917-3921.

 

  1. Tamanoi, F., Engler, M.J., Lechner, R., Orr-Weaver, T., Romano, L.J., Saito, H., Tabor, S. and Richardson, C.C. (1980) In: Mechanistic Studies of DNA Replication and Genetic Recombination, (B. Alberts, ed.) Academic Press, New York, pp. 411-428.

 

  1. Romano, L.J., Tamanoi, F. and Richardson, C.C. (1981) Initiation of DNA repication at the primary origin of bacteriophage T7 by purified proteins: requirements for T7 RNA polymerase. Proc. Natl. Acad. Sci. USA 78, 4107-4111.

 

  1. Deuring, R., Winterhoff, U., Tamanoi, F., Stabel, S., and Doerfler, W. (1981) Site of linkage between adenovirus type 12 and cell DNAs In hamster tumor line CLAC3. Nature 293, 5827, 81-84.

 

15. Tamanoi, F., and Stillman, B.W. (1982) Function of adenovirus terminal protein in the initiation             of DNA replication. Proc. Natl. Acad. Sci. USA 79, 2221-2225.

 

  1. Stillman, B.W. and Tamanoi, F. (1982) Adenovirus DNA replication: DNA sequences and enzymes required for initiation in vitro. Cold Spring Harbor Symp. Quant. Biol. 47, 741-750.

 

  1. Stillman, B.W., Tamanoi, F., and Mathews, M.B. (1982) Purification of an adenovirus coded DNA polymerase that is required for initiation of DNA replication. Cell 31, 613-623.

 

  1. Tamanoi, F., and Stillman, B.W. (1983) Initiation of adenovirus DNA replication in vitro requires a specific DNA sequence. Proc. Natl. Acad. Sci. USA 80, 6446-6450.

 

  1. Tamanoi, F. and Stillman, B.W. (1983) The origin of adenovirus DNA replication. In: Current Topics in Microbiology and Immunology. 109, 75-87.

 

  1. Guggenheimer, R.A., Stillman, B.W., Nagata, K., Tamanoi, F. and Hurwitz, J. (1984) DNA sequences required for the in vitro replication of adenovirus DNA. Proc. Natl. Acad. Sci. USA 81, 3069-3073.

 

  1. Hughes, S., Mellstrom, K., Kosik, E., Tamanoi, F., and Brugge, J. (1984) Mutation of a termination codon affects src initiation. Mol. Cell. Biol. 4, 1738-1746.

 

  1. Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth, M. and Wigler, M. (1984) Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc. Natl. Acad. Sci. USA 81, 4008-4012.

 

  1. Tamanoi, F., Walsh, M., Kataoka, T., and Wigler, M. (1984) A product of yeast RAS2 gene is a guanine nucleotide binding protein. Proc. Natl. Acad. Sci. USA 81, 6924-6928.

 

  1. Tamanoi, F., Rao, M., Samiy, N., and Walsh, M. (1985) Enzymatic properties of yeast RAS2 protein. In: Cancer Cells 3, 251-256 (Cold Spring Harbor Laboratory).

 

  1. Broek, D., Samiy, N., Fasano, O., Fujiyama, A., Tamanoi, F., Northup, J., and Wigler, M. (1985) Differential activation of yeast adenylate cyclase by wild-type and mutant RAS proteins. Cell 41, 763-769.

 

  1. Tamanoi, F. (1986) On the mechanism of adenovirus DNA replication. In: Develop-ments in Molecular Virology Vol. 8, “Adenovirus DNA: The Viral Genome and Its Expression” (W. Doerfler, ed.), Martinus Nijhoff Publishing, Boston, pp. 97-128.

 

  1. Fujiyama, A. and Tamanoi, F. (1986) Processing and fatty acylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 83, 1266-1270.

 

  1. Fujiyama, A., Samiy, N., Rao, M. and Tamanoi, F. (1986) Biochemistry of yeast RAS1 and RAS2 proteins. In: Yeast Cell Biology (ed. Hicks, J.) Alan R. Liss, Inc., New York, pp. 125-149.

 

  1. Fujiyama, A., Matsumoto, K., and Tamanoi, F. (1987) A novel yeast mutant deficient in the processing of ras proteins: Assessment of the effect of the mutation on processing steps. EMBO J. 6, 223-228.

 

  1. Tamanoi, F., Hseuh, E.C., Goodman, L.E., Cobitz, A.R., Detrick, R.J., Brown, W.R., and Fujiyama, A. (1988) Post-translational modification of ras proteins: Detection of a modification prior to fatty acid acylation and cloning of a gene responsible for the modification. J. Cell. Biochem. 36, 261-273.

 

  1. Tamanoi, F. (1988). Yeast RAS genes. Biochem. Biophys. Acta 948, 1-15.

 

32. Goodman, L.E., Perou, C.M., Fujiyama, A. and Tamanoi, F. (1988) Structure and expression of                 yeast DPR1, a gene essential for the processing and intracellular localization of ras proteins.                     Yeast 4, 271-281.

 

  1. Cobitz, A.R., Yim E.H., Brown, W.R., Perou, C.M. and Tamanoi, F. (1989) Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 86, 858-862.

 

  1. Tamanoi, F., Cobitz, A.R., Fujiyama, A., Goodman, L.E. and Perou, C.M. (1989) Post-translational modification of ras proteins: Palmitoylation and phosphorylation of yeast RAS proteins. In: RAS Oncogenes (ed. D. Spandidos) Plenum Press, New York and London, 225-233.

 

  1. Fujiyama, A. and Tamanoi, F. (1990) RAS2 protein of S. cerevisiae undergoes removal of methionine at N-terminus and removal of three amino acids at C-terminus. J. Biol. Chem. 265, 3362-3368.

 

  1. Finegold, A.A., Schafer, W.R., Rine, J., Whiteway, M., and Tamanoi, F. (1990) Common modifications of trimeric G proteins and ras protein: Involvement of polyisoprenylation. Science 249, 165-171.

 

  1. Tanaka, K., Nakafuku, M., Tamanoi, F., Kaziro, Y., Matsumoto, K., and Toh-e, A. (1990) IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase activating protein. Mol. Cell. Biol. 10, 4303-4313.

 

  1. Goodman, L.E., Judd, S.E., Farnsworth, C.C., Powers, S., Gelb, M.H., Glomset, J.A. and Tamanoi, F. (1990) Mutants of Saccharomyces cerevisiae defective in the farnesylation of ras proteins. Proc. Natl. Acad. Sci. USA 87, 9665-9669.

 

  1. Xu, G., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., Weiss, R. and Tamanoi, F. (1990) The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63, 835-841.

 

  1. Tanaka, K., Lin, B.K., Wood, D.R. and Tamanoi, F. (1991) IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase activating protein (GAP). Proc. Natl. Acad. Sci. USA 88, 468-472.

 

  1. Tamanoi, F. (1996) DPR1/RAM1. In Guidebook to the small GTPases (eds. Zerial, M. and Huber, L.) Oxford University Press, 52-56.

 

  1. Tamanoi, F. (1996) RAM2. In Guidebook to the small GTPases (eds. Zerial, M. and Huber, L.) Oxford University Press, 50-52.

 

  1. Judd, S.R. and Tamanoi, F. (1991) A genetic approach to the study of farnesylation. “Methods” A companion to Methods in Enzymology 1, 246-252.

 

  1. Finegold, A.A., Johnson, D.I., Farnsworth, C.C., Gelb, M.H., Judd, S.R., Glomset, J.A. and Tamanoi, F. (1991) Protein geranylgeranyl transferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product, but not the DPR1 gene product. Proc. Natl. Acad. Sci. USA 88, 4448-4452.

 

  1. Ohya, Y., Goebel, M., Goodman, L.E., Petersen-Bjorn, S., Friesen, J.D., Tamanoi, F. and Anraku, Y. (1991) Yeast CAL1 is a structural and functional homologue to the DPR1 (RAM) gene involved in ras processing. J. Biol. Chem. 266, 12356-12360.

 

  1. Fujiyama, A., Tsunasawa, S., Tamanoi, F. and Sakiyama, F. (1991) S-Farnesylation and methyl esterification of C-terminal domain of yeast RAS2 protein prior to fatty acid acylation. J. Biol. Chem 266, 17926-17931.
  2. Golubic, M., Tanaka, K., Dobrowski, S., Wood, D., Tsai, M.H., Marshall, M., Tamanoi, F. and Stacey, D.W. (1991) The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. The EMBO J. 10, 2897-2903.

 

  1. McNeel, D.G. and Tamanoi, F. (1991) Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids. Proc. Natl. Acad. Sci. USA 88, 11398-11402.

 

  1. Tanaka, K., Wood, D.R., Lin, B.K., Khalil, M., Tamanoi, F. and Cannon, J.F. (1992) A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity. Mol. Cell. Biol. 12, 631-637.

 

  1. Gomez, R., Goodman, L.E., Tripathy, S.K., O’Rourke, E., Manne, V. and Tamanoi, F. (1992) Purified yeast protein farnesyltransferase is structurally and functionally similar to its mammalian counterpart. Biochem. J., 289, 25-31.

 

  1. Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M. and Tamanoi, F. (1993) Identification of ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90, 2281-2285.

 

  1. Tamanoi, F. (1993) Inhibitors of ras farnesyltransferases. TIBS, 18, 349-353.

 

  1. Wilson, B., Khalil, M., Tamanoi, F. and Cannon, J.F. (1993) New activated RAS2 9

mutations identified in Saccharomyces cerevisiae. Oncogene, 8, 3441-3445.

 

  1. Diaz, M., Sanchez, Y., Bennett, T., Sun, C.R., Godoy, C., Tamanoi, F., Duran, A. and Perez, P. (1993) The Schizosaccharomyces pombe cwg2+ gene codes for the ß subunit of a geranylgeranyltransferase type I required for ß-glucan synthesis. The EMBO Journal. 12, 5245-5254.

 

  1. Poullet, P., Lin, B., Esson, K. and Tamanoi, F. (1994) Functional significance of lysine-1423 of neurofibromin and characterization of a second site suppressor which rescues mutation at this residue and suppresses RAS2val19 activated phenotypes. Mol. Cell. Biol. 14, 815-821.

 

  1. Wood, D.R., Poullet, P., Wilson, B.A., Khalil, M., Tanaka, K., Cannon, J.F. and Tamanoi, F. (1994) Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase activating proteins. J. Biol. Chem. 269, 5322-5327.

 

  1. Cohen, L., Mohr, R., Chen, Y-Y, Huang, M., Kato, R., Dorin, D., Tamanoi, F., Goga, A., Afar, D., Rosenberg, N. and Witte, O. (1994) Transcriptional activation of a novel ras-like gene (kir) by oncogenic tyrosine kinases. Proc. Natl. Acad. Sci. USA 91, 12448-12452.

 

  1. Mitsuzawa, H., Esson, K. and Tamanoi, F. (1995) Mutant farnesyltransferase ß subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I ß subunit. Proc. Natl. Acad. Sci. USA 92, 1704-1708.

 

  1. Mitsuzawa, H. and Tamanoi, F. (1995) In vivo assays for farnesyltransferase inhibitors with Saccharomyces cerevisiae. Methods in Enzymology 250, 43-51.

 

  1. Tamanoi, F. and Mitsuzawa, H. (1995) Use of yeast for the identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. (1995) Methods in Enzymology 255, 82-91.

 

  1. Poullet, P. and Tamanoi, F. (1995) Use of the yeast two-hybrid system to evaluate Ras interactions with neurofibromin-GAP. Methods in Enzymology 255, 488-497.
  2. Baba, H., Fuss, B., Urano, J., Poullet, P., Watson, J.B., Tamanoi, F. and Macklin, W.B. (1995) GapIII, a new brain-enriched member of the GTPase-activating protein family. J. Neurosci. Res. 41, 846-858.

 

  1. Gelb, M.H., Tamanoi, F., Yokoyama, K., Ghomashchi, F., Esson, K. and Gould, M.N. (1995) The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Letters 91, 169-175.

 

  1. Dorin, D., Cohen, L., DelVillar, K., Poullet, P., Mohr, R., Whiteway, M., Witte, O. and Tamanoi, F. (1995) Kir, a novel ras-family G-protein induces pseudohyphal growth in Saccharomyces cerevisiae. Oncogene 11, 2267-2271.

 

  1. Morcos, P., Thapar, N., Tusneem, N., Stacey, D. and Tamanoi, F. (1996) Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Mol. Cell. Biol. 16, 2496-2503.

 

  1. Del Villar, K., Dorin, D., Sattler, I., Urano, J., Poullet, P., Robinson, N., Mitsuzawa, H. and Tamanoi, F. (1996) C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem Soc. Trans. 24, 709-713.

 

  1. Sattler, I. and Tamanoi, F. (1996) Prenylation of Ras and inhibitors of prenyltransferases. In Regulation of the RAS signalling network (ed. H. Maruta) Molecular Biology Intelligence Unit Series, R.G. Landes, Austin, TX. pp 95-137.

 

  1. Del Villar, K., Mitsuzawa, H., Yang, W-L, Sattler, I. and Tamanoi, F. (1997) Amino acid substitutions which convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase I. J. Biol. Chem. 272, 680-687.

 

  1. Upadhaya, M, Osborn, M., Maynard, J., Kim, M.R., Tamanoi, F. and Cooper, D. (1997) Mutational and functional analysis in the neurofibromatosis type 1 (NF1) gene. Human Genet. 99, 88-92.

 

  1. Yang, W., Del Villar, K., Urano, J., Mitsuzawa, H. and Tamanoi, F. (1997) Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein

farnesyltransferase. J. Cellular Biochem, S27, 12-19.

 

  1. Scoles, D.R., Huynh, D.P., Morcos, P.A., Coulsell, E.R., Robinson, N.G.G., Tamanoi, F. and Pulst, S.M. (1998) Neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin. Nature Genet. 18, 354-359.

 

  1. Kim, M.R. and Tamanoi, F. (1998) Neurofibromatosis 1 GTPase activating protein-related domain and its functional significance. In Neurofibromatosis type 1: from genotype to phenotype. (Upadhyaya, M. and Cooper, D.N. eds) BIOS Scientific, Oxford, UK. pp 89-112.

 

  1. Arellano, M., Coll, P.M., Yang, W., Duran, A., Tamanoi, F. and Perez, P. (1998) Characterization of geranylgeranyl transferase type I from Schizosaccharomyces pombe. Molecular Microbiology, 29, 1357-1367.

 

  1. Suzuki, N., Del Villar, K. and Tamanoi, F. (1998) Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells which are blocked by microtubule interfering agents. Proc. Natl. Acad. Sci. USA 95, 10499-10504.

 

  1. Suzuki, N., Urano, J. and Tamanoi, F. (1998) Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA 95, 15356-15361.
  2. Robinson, N.G.G., Guo, L., Imai, J., Toh-e, A., Matsui, Y. and Tamanoi, F. (1999) Rho3 of Saccharomyces cerevisiae, which regulated the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70. Mol.Cell. Biol. 19, 3580-3587.

 

  1. Urano, J. and Tamanoi, F. (1999) Reconstitution of yeast farnesyltransferase from individually purified subunits. In Protein Lipidation Protocols, ed. M. Gelb, Humana Press, NJ, 145-159.

 

  1. Del Villar, K., Urano, J., Guo, L. and Tamanoi, F. (1999) A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J. Biol. Chem. 274, 27010-27017.

 

  1. Yang, W., Urano, J. and Tamanoi, F. (2000) Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. J. Biol. Chem. 275, 429-438.

 

  1. Urano, J., Tabancay, A.P., Yang, W. and Tamanoi, F. (2000) The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. J. Biol. Chem 275, 11198-11206.

 

  1. Edamatsu, H., Gau, C-L., Nemoto, T., Guo, L. and Tamanoi, F. (2000) Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19, 3059-3068.

 

  1. Tamanoi, F., Del Villar, K., Robinson, N.G.G., Urano, J. and Yang, W. (2000) Genetic analysis of FTase and GGTase I and natural product farnesyltransferase inhibitors. In Farnesyltransferase and geranylgeranyltransferase I: Targets for cancer and cardiovascular therapy. (eds, Sebti and Hamilton) Humana press, Totowa, NJ, pp 145-157.

 

  1. Urano, J., Yang, W. and Tamanoi, F. (2000) Mutational analyses of protein farnesyltransferase . In The Enzymes, vol 21, Protein Lipidation. (eds. Tamanoi and Sigman), Academic Press, San Diego, CA, pp 48-80.

 

  1. Chia, S., Urano, J., Tamanoi, F., Dunn, B. and Zink, J.I. (2000) Patterned arrays of living cells in Sol-Gel silica films. J. Am. Chem. Soc. 122, 6488-6489.

 

  1. Urano, J., Ellis, C., Clark, G.J. and Tamanoi, F. (2000) Characterization of Rheb function using yeast and mammalian systems. Methods in Enzymology 333, 217-231.

 

  1. Guo, W., Tamanoi, F. and Novick, P. (2001) Spatial regulation of the exocyst complex by Rho1 GTPase. Nature Cell Biol. 3, 353-360.

 

  1. Pervin, S., Singh, R., Gau, C-L., Edamatsu, H., Tamanoi, F. and Chaudhuri, G. (2001) Potentiation of nitric oxide induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: Implications in breast cancer. Cancer Res. 61, 4704-4706.

 

  1. Yang, W., Tabancay, A.P.Jr., Urano, J. and Tamanoi, F. (2001) Failure to farnesylated Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol. Microbio. 41, 1339-1347.

 

  1. Finlin, B.S., Gau, C.L., Murphy, G.A., Shao, H., Kimel, T., Seitz, R.S., Chiu, Y.F., Botstein, D., Brown, P.O., Der, C.J., Tamanoi, F., Andres, D.A. and Perou, C.M. (2001) Rerg is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. J. Biol. Chem. 276, 42259-42267.

 

  1. Tamanoi, F., Gau, C.L., Edamatsu, H., Jiang, C. and Kato-Stankiewicz, J. (2001) Protein farnesylation in mammalian cells: Effects of farnesyltransferase inhibitors on cancer cells. Cell. Mol. Life Sci. 58, 1-14.
  2. Jiang, C., Kato-Stankiewicz, J., Gau, C.L. and Tamanoi, F. (2001) Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells. Gene Funct. Dis. 2/3, 1-9.

 

  1. Tamanoi, F., Kato-Stankiewicz, J., Jiang, C., Machado, I. and Thapar, N. (2001) Farnesylated proteins and cell cycle progression. J. Cell. Biochem. 37, 6-70.

 

  1. Kato-Stankiewicz, J., Hakim, I., Zhi, G., Zhang, J., Serebriiskii, I., Guo, L., Edamatsu, H., Koide, H., Menon, S., Eckl, R., Sakamuri, S., Lu, V., Chen, Q., Agarwal, S., Baumbach, W.R., Golemis, E.A., Tamanoi, F. and Khazak, V. (2002) Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA 99, 14398-14403.

 

  1. Hamasaki, A., Naka, H., Tamanoi, F., Umezawa, K. and Otsuka, M. (2003) A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg. Med. Chem. Lett. 13, 1523-1526.

 

  1. Patel, P.H., Thapar, N., Guo, L., Martinez, M., Maris, J., Gau, C-L., Lengyel, J.A. and Tamanoi, F. (2003) Drosphila Rheb GTPase is required for cell cycle progression and cell growth. J. Cell Sci. 116, 3601-3610.

 

  1. Tabancay, A.P.Jr., Gau, C-L., Machado, I.M.P., Uhlmann, E.J., Gutmann, D.H., Guo, L. and Tamanoi, F. (2003) Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278, 39921-39930.

 

  1. Clarke, S. and Tamanoi, F. (2004) Fighting cancer by disrupting C-terminal methylation of signaling proteins. J. Clin. Invest. 113, 513-515.

 

  1. Aspuria, P-J. and Tamanoi, F. (2004) The Rheb family of GTP-binding proteins. Cellular Signaling 16, 1105-1112.

 

  1. Uhlmann, E.J., Li, W., Scheidenhelm, D.K., Gau, C.L., Tamanoi, F. and Gutmann, D.H. (2004) Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia, 47, 180-188.

 

  1. Kho, Y., Kim, S.C., Jiang, C., Barma, D., Kwon, S.W., Cheng, J., Weinbaum, C., Tamanoi, F., Falck, J. and Zhao, Y. (2004) A novel tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc. Natl. Acad. Sci. USA 101, 12479-12484.

 

  1. Gau, C.L., Kato-Stankiewicz, J., Jiang, C., Miyamoto, S., Guo, L. and Tamanoi, F. (2005) Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and insensitive pathways. Molec. Cancer Therap. 4, 918-926.

 

  1. Urano, J., Comiso, M.J., Guo, L., Aspuria, P-J., Deniskin, R., Tabancay, A.P. Jr., Kato Stankiewicz, J. and Tamanoi, F. (2005) Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Mol. Microbiol. 58, 1074-1086.

 

  1. Khazak, V. Kato-Stankiewicz, J., Tamanoi, F, and Golemis, E.A. (2006) Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction. Methods in Enzymol. 407. 612-629.

 

  1. Patel, P.H. and Tamanoi, F. (2006) Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. Methods in Enzymol. 407. 443-454.

 

  1. Ikeda, A., Shankar, D.B., Watanabe, M., Tamanoi, F., Moore, T.B. and Sakamoto, K.M.

(2006) Molecular targets and the treatment of myeloid leukemia. Mol. Genet. Metab. 88, 216-224.

 

  1. Tabancay, A.P.Jr., Comiso, M.J. and Tamanoi, F. (2006) RAS family G-proteins in Saccharomyces cerevisiae and Schizosaccharomyces pombe. In RAS family GTPases, ed. Der, C., Springer, pp. 227-256.

 

  1. Patel, P.H. and Tamanoi, F. (2006) Increased Rheb/TOR signaling enhances sensitivity of the whole organism to oxidative stress. J. Cell. Sci. 119, 4285-4292.

 

  1. Gelb, M.H., Brunsveld, L., Hrycyna, C.A., Michaelis, S., Tamanoi, F., Van Voorhis, W.C. and Waldmann, H. (2006) Protein prenylation and associated modification: Opportunities for therapeutic intervention. Nature Chem. Biol. 10, 518-528.

 

  1. Matsuo, T., Ohtsubo, Y., Urano, J., Tamanoi, F. and Yamamoto, M. (2007) Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast. Mol. Cell. Biol. 27, 3154-3164.

 

  1. Urano, J., Sato, T., Matsuo, T., Ohtsubo, Y., Yamamoto, M. And Tamanoi, F. (2007) point mutations in TOR confer Rheb-indepedent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc. Natl. Acad. Sci. USA 104, 3514-3519.

 

  1. Yu, F., Harada, J.N., Brown, H.J., Deng, H., Song, M.J., Wu, T-T., Kato-Stankiewicz, J., Nelson, C.G., Vieira, J., Tamanoi, F., Chanda, S.K. and Sun, R. (2007) Systematic identification of cellular signals reactivating Kaposi’s sarcoma-associated herpesvirus. PLOS Pathogen, 3, e44.

 

  1. Castellano, S., Fiji, H.D., Kinderman, S.S., Watanabe, M., Leon, P.D., Tamanoi, F. and Kwon, O. (2007) Small molecule inhibitors of protein geranylgeranyltransferase type I. J. Am. Chem. Soc. 129, 5843-5845.

 

  1. Lu, J., Liong, M., Zink, J.I. and Tamanoi, F. (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3, 1341-1346.

 

  1. Thapar, N. and Tamanoi, F. (2007) Study of protein farnesylation in yeast. In Yeast as a Tool in Cancer Research. eds. Nitiss, J.L. and Heitman, J., Springer, pp. 101-122.

 

  1. Aspuria, P.J., Sato, T. and Tamanoi, F. (2007) The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: Temperature sensitive and constitutive active mutants of TOR. Cell Cycle, 6, 1692-1695.

 

  1. Lu, J., Liong, M., Sherman, S., Xia, T., Kovochich, M., Nel. A.E., Zink, J.I. and Tamanoi, F. (2008) Mesoporous silica nanoparticles for cancer therapy: Energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. NanoBiotechnology 3, 89-95.

 

  1. Watanabe, M., Fiji, H.D., Guo, L., Chan, L., Kinderman, S.S., Slamon, D.J., Kwon, O. and Tamanoi, F. (2008) Inhibitors of protein geranylgeranyltransferase-I and Rab geranylgeranyltransferase identified from a library of allenoate derived compounds. J. Biol. Chem. 283, 9571-9579.

 

  1. Ikeda, K., Morigasaki, S., Tatebe, H., Tamanoi, F. and Shiozaki, K., (2008) Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell Cycle 7, 358-364.

 

  1. Lu, J., Choi, E., Tamanoi, F. and Zink, J.I. (2008) Light-activated nanoimpellers controlled drug release in cancer cells. Small 4, 421-426.

 

  1. Sato, T., Umetsu, A. and Tamanoi, F. (2008) Characterization of the Rheb-mTOR signaling pathway in mammalian cells: Constitutive active mutants of Rheb and mTOR. Methods Enzymol. 438, 307-320.

 

  1. Aspuria, P.J. and Tamanoi, F. (2008) The TSC/Rheb/TOR signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Mol. Genet. Genomics. 279, 441-450.

 

  1. Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S.G., Nel, A.E., Tamanoi, F. and Zink, J.I. (2008) Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS NANO 2, 889-896.

 

  1. Short, J.D., Houston, K.D., Dere, R., Cai, S.L., kim, J., Johnson, C.L., Broaddus, R.R., Shen, J., Miyamoto, S., Tamanoi, F., Kwiatkowski, D., Mills, G.B. and Walker, C.L. (2008) AMP-activated protein kinase signalin results in cytoplasmic sequestration of p27. Cancer Res. 68, 6496-6506.

 

  1. Davies, B.S., Yang, S.H., Farber, E., Lee, R., Buck, S.B., Andres, D.A., Spielmann, H., Agnew, B.J., Tamanoi, F., Fong, L.G. and Young, S.G. (2008) Increasing the length of

progerin’s isoprenyl anchor does not worsen bone disease or survival in mice with

Hutchinson-Gilford progeria syndrome. J. Lipid Res. 50, 126-134.

 

  1. Zhou, J., Vos, C.C., Gjyrezi, A., Yoshida, M., Khuri, F.R., Tamanoi, F. and Giannakakou, P. (2009) The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J. Biol. Chem. 284, 9648-9655.

 

  1. Klichko, Y., Liong, M., Choi, E., Angelos, S., Nel, A.E., Stoddart, J.F., Tamanoi, F. and Zink, J.I. (2009) Mesoporous silica for optical functionality, nanomachines, and drug delivery. J. Am. Ceram. Soc. 92, S2-S10.

 

  1. Sato, T., Nakashima, A., Guo, L. and Tamanoi, F. (2009) Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J. Biol, Chem. 284, 12783-12791.

 

  1. Kugawa, F., Suzuki, T., Miyata, M., Tomono, K. And Tamanoi, F. (2009) Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie 64, 296-300.

 

  1. Lu, J., Chan, L., Fiji, H.D.G., Dahl, R., Kwon, O. and Tamanoi, F. (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I, Mol. Cancer Ther. 8, 1218-1226.

 

  1. Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, Der CJ. (2010) Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene 29(3):380-91.

 

  1. Sato T, Nakashima A, Tamanoi F. (2010) Rheb-mTOR signaling pathway involved in tumor formation. Tanpakushitsu Kakusan Koso. 55(1):11-7. Review. Japanese.

 

  1. Nakashima A, Sato T, Tamanoi F. (2010) Fission yeast TORC1 regulate phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. J Cell Sci. 123(Pt 5):777-86.

 

  1. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 29(18):2746-52.

 

  1. Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F. (2010) Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 6(11):1185-90.

 

  1. Chan, L., Hart, Hart, C., Guo, L., Nyberg, T., Davides, B., Fong, L., Young, S., Agnew, B., Tamanoi, F. (2010) A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis. 30, 3598-3606. PMCID: PMC2855049

 

  1. Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J. (2010) Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. PNAS 107(25):11234-9.

 

  1. Parmar, N. and Tamanoi F. (2010) Rheb G-Proteins and the activation of mTORC1. The Enzymes. 27: 39-53.

 

  1. Chantaravisoot, N. and Tamanoi F. (2010) TOR Signaling and Human Cancer. The Enzymes. 28: 301-314.

 

  1. Lu J, Liong M, Li Z, Zink J, Tamanoi F. (2010) Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 6:1794-805.

 

  1. Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE. (2010) Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J Am Chem Soc. 132(36):12690-7.

 

  1. Hardt M, Chantaravisoot N, Tamanoi F. (2011) Activating mutations of TOR (target of rapamycin). Genes Cells. 16(2): 141-51.

 

  1. Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI. (2011) Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small. 7, 1816-1826.

 

  1. Xue M, Zhong X, Shaposhnik Z, Qu Y, Tamanoi F, Duan X, Zink JI. (2011) pH-operated mechanized porous silicon nanoparticles. J Am Chem Soc. Jun 15; 133(23):8798-801.

 

  1. Tamanoi, F. (2011) Ras signaling in yeast. Genes Cancer 2, 210-215

 

  1. Chan, L.N., Fiji, H.D., Watanabe, M., Kwon, O. and Tamanoi, F. (2011) Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis- based inhibitor of geranylgeranyltransferase-I. PLoS One 6, e2613

 

  1. Lu J, Li Z, Zink JI, Tamanoi F. (2012) In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine. 8, 212-220. NIHMSID 313291.

 

  1. Yanes, R.E. and Tamanoi, F. (2012) Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic Delivery 3, 389-404.

 

  1. Lau Y.A., Henderson B.L., Lu J, Ferris D.P., Tamanoi F, Zink J.I. (2012) Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a living cell. Nanoscale 4, 3482-3489.

 

  1. Nakashima, A., Otsubo, Y., Yamashita, A., Sato, T, Yamamoto, M and Tamanoi, F. (2012) Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 as S6 kinase. J Cell Sci 125, 5840-5849.

 

  1. Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F (2012) PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One 7(7):e42012.

 

  1. Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F. (2013) Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small 9, 697.

 

  1. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. (2013) De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery, 3, 534-547.

 

  1. Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F (2013) In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC Cancer 13, 198.

 

  1. Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F (2014) Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. J Biol Chem. 289, 4723-4734.

 

  1. Croissant J, Maynadier M, Gallud A, Peindy N’dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Tarn D, Guardado-Alvarez TM, Zink JI. (2014) Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angew Chem Int Ed Engl. 52, 13813-13817.

 

  1. Croissant J, Chaix A, Mongin O, Wang M, Clement S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI. (2014) Two-photon-triggered drug delivery via fluorescent nanovalves (2014) Small 10, 1752-1755. PMID:24678053

 

  1. Heard JJ, Fong V, Bathaie SZ, Tamanoi F (2014) Recent progress in the study of the Rheb family GTPases. Cell Signal. 26, 1950-1957.

 

  1. Nakashima A, Kamada S, Tamanoi F, Kikkawa U (2014) Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biol Open. 3, 542-52.

 

  1. Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M. (2014) Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Chemistry, 20, 9372-9380. PMID: 24986399.

 

  1. Hwang AA, Lu J, Tamanoi F, Zink J (2014) Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small 11, 319-328. Doi: 10.1002/smll.201400765. PMID: 25196485. PMCID: PMC4327898.

 

  1. Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S. (2015) Rheb protein binds CAD (Carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. J Biol Chem. 290, 1096-105. doi: 10.1074/jbc.M114.592402. Epub 2014 Nov 24.

 

  1. Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F. (2015) Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis, BMC Cancer 15, 381. doi: 10.1186/s12885-015-1360-4.

 

  1. Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA (2015) Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine. 11, 1657-1666. doi: 10.1016/j.nano.2015.05.011.

 

  1. Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F (2015) Significance of filamin A in mTORC2 function in glioblastoma. Mol Cancer. 14(1):127. oi: 10.1186/s12943-015-0396-z.

 

  1. Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F (2015) Nanoformulation of geranylgeranyltransferase-I inhibitors for cancer therapy: Liposomal encapsulation and pH-dependent delivery to cancer cells. PLOS ONE doi:10.1371/journal.pone.0137595.

 

  1. Mekaru H, Lu J, Tamanoi F (2015) Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv Drug Deliv Rev. 95, 40-49. PMCID: PMC4663124.

 

  1. Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM (2016) Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in vivo tumor imaging. J. Control Release 229, 183-191.

 

  1. Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM (2016) Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry. 22, 9607-9615.

 

  1. Croissant J, Fatieiev Y, Julfakyan K, Lu J, Emwas A, Anjum D, Omar H, Tamanoi F, Zink J, Khashab N (2016) Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry. 22, 14806-14811.

 

  1. Bathaie S, Ashrafi M, Azizian M, Tamanoi F (2017) Mevalonate pathway and human cancers. Curr Mol Pharmacol. 10, 77-85.

 

  1. Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi, F, Glackin CA (2017) Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models Nanomedicine 13, 965-976.

 

  1. Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otuska M (2017) A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorg Med Chem Lett 27, 3862-3866.

 

  1. Hayashi JY and Tamanoi, F. (2017) Exploiting enzyme alterations in cancer for drug activation, drug delivery and nanotherapy. The Enzymes 42, 153-172.

 

  1. Heard, J.J., Phung I, Potes MI and Tamanoi F. (2018) An oncogenic mutant of RHB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18, 69.

 

  1. Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F and Mohaghedhi MA. (2018) Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women’s breast cancer tumors. Cytotechnology 70, 625-639.

 

  1. Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer, J, Tamanoi F, Zink, JI and Glackin CA. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14, 1381-1394.

 

  1. Doura T, Tamanoi F and Nakamura M. (2018) Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. J. Colloid Interface Sci. 526, 51-62.

 

  1. Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Doan, T, Yik T, Siargi S, Contreras A, Ratliff L, Jimenez CM, Raehm,L, Khashab N, Durand JO, Glackin C and Tamanoi F. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8, 8524.

 

  1. Mekaru H, Yoshigoe A, Nakamura M, Doura T and Tamanoi F. (2019) Biodegradability of disulfide-organosilica nanoparticles evaluated by soft X-ray photoelectron spectroscopy: Cancer therapy implications. ACS Appl. Nano Mater. 2, 479-488.

 

  1. Doura T, Nishio T, Tamanoi F. Nakamura M. (2019) Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures. J. of Materials Research 2019; doi: 10.1557/jmr.2018.501.

 

  1. Matsumoto K, Saitoh H, Doan TLH, Shiro A, Nakai K, Komatsu A, Tsujimoto M, Yasuda R, Kawachi T, Tajima T, Tamanoi F. (2019) Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. Sci Rep. 9:13275

 

  1. Komatsu A, Matsumoto K, Saito T, Muto M, Tamanoi F. (2019) Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. Cells. 10;8(5).

 

  1. Mai NXD, Birault A, Matsumoto K, Tan HKT, Intasa-ard SG, Morrison K, Thang PB, Doan TLH, Tamanoi F. (2020) Biodegradable periodic mesoporous organosilica (BPMO) loaded with daunorubicin: A promising nanoparticle-based anticancer drug. ChemMedChem 15, 1-8.

 

  1. Tamanoi F, Matsumoto K, Doan TLH, Shiro A, Saitoh H. (2020) Studies on the exposure of gadolinium containing nanoparticles with monochromatic X-rays drive advances in radiation therapy. Nanomaterials 10, 1341. doi: 10.3390/nano10071341